Announcements Trials
Browse Landscape

Phase

Phase 2 25Phase 1/2 6Phase 1 5Phase NA 4Phase 3 4Phase 4 1

Status

Unknown 1Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 53Carcinoma, Hepatocellular 40Neoplasms 38Polycystic Ovary Syndrome 27Colorectal Neoplasms 24Stomach Neoplasms 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Carcinoma, Non-Small-Cell Lung 17Prostatic Neoplasms 15Recurrence 13Pancreatic Neoplasms 13Lymphoma 13Liver Neoplasms 12Urinary Bladder Neoplasms 11Leukemia, Myeloid, Acute 11Esophageal Neoplasms 11Leiomyoma 10Colonic Neoplasms 10Pain 9Lung Neoplasms 9Multiple Myeloma 8Uterine Cervical Neoplasms 7Neoplasm Metastasis 7Lymphoma, Non-Hodgkin 7Lymphoma, Follicular 7Keratosis, Actinic 7Infertility 7Papillomavirus Infections 6Pain, Postoperative 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6

Interventions

disitamab vedotin 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Unknown × Carcinoma, Transitional Cell × Clear all
NCT05723991 2023-02-13

Study of Disitamab Vedotin Combined With Gemcitabine in Neoadjuvant Treatment of Urothelial Carcinoma

Tongji Hospital

Phase 4 Unknown
36 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡